Restructuring liabilities Restructuring liabilities Restructuring Reserve, Current Deferred Revenue Arrangement, by Type [Table] Deferred Revenue Arrangement, by Type [Table] Range [Domain] Statistical Measurement [Domain] Gross Unrealized Loss Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Cover [Abstract] Increase in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect AB-101-001 Phase 1a/1b clinical trial expense AB-101-001 Phase 1a/b clinical trial expense AB-101-001 Phase 1a/b clinical trial expense Trading Symbol Trading Symbol Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Ownership interest in equity method investment (as a percentage) Equity Method Investment, Ownership Percentage All Trading Arrangements All Trading Arrangements [Member] Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Non-NEOs Non-NEOs [Member] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Equity investment Equity Method Investments Pay vs Performance Disclosure [Line Items] Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Accounts receivable Increase (Decrease) in Accounts Receivable Restructuring And Workforce Reduction Restructuring And Workforce Reduction [Member] Restructuring And Workforce Reduction Effective annual interest rate on royalty liability Effective Annual Interest Rate Of Royalty Liability Effective Annual Interest Rate Of Royalty Liability Net loss attributable to common shareholders per share Earnings Per Share, Policy [Policy Text Block] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Issuance of common shares upon vesting of RSUs Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Fair value measurements Fair Value Disclosures [Text Block] Issuance of common shares pursuant to exercise of stock options Proceeds from Stock Options Exercised Restructuring and Related Activities [Abstract] Award Timing Disclosures [Line Items] Short Term Marketable Securities Investments in marketable securities, current [Member] Investments in marketable securities, current Investment, Name [Domain] Investment, Name [Domain] Other Performance Measure, Amount Other Performance Measure, Amount Common shares, shares outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Outstanding Moderna And Pfizer/BioNTech Moderna Therapeutics, Inc And Pfizer Inc And BioNTech SE [Member] Moderna Therapeutics, Inc And Pfizer Inc And BioNTech SE Lease liability, non-current Operating Lease, Liability, Noncurrent Revenue from Contract with Customer [Abstract] Plan Name [Domain] Plan Name [Domain] Accrued lease-related operating expenses Accrued lease-related operating expenses Accrued Rent Other non-current assets Other Assets, Noncurrent Entity Tax Identification Number Entity Tax Identification Number Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Money market Money Market Funds [Member] Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities OPERATING ACTIVITIES Net Cash Provided by (Used in) Operating Activities [Abstract] Issuance of common shares pursuant to the Open Market Sale Agreement Stock Issued During Period, Value, New Issues, Open Market Sale Agreement Stock Issued During Period, Value, New Issues, Open Market Sale Agreement Premium on closing stock price ($ paid) Premium on closing stock price ($ paid) Premium on closing stock price ($ paid) Costs related to collaboration Other Cost and Expense, Operating Plan Name [Axis] Plan Name [Axis] Equity Components [Axis] Equity Components [Axis] Award Timing Method Award Timing Method [Text Block] One-Time Upfront Cash Payment One-Time Upfront Cash Payment [Member] One-Time Upfront Cash Payment Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Restructuring Type [Axis] Restructuring Type [Axis] Fair Value Investments in marketable securities, fair value Debt Securities, Available-for-Sale Measurement Frequency [Axis] Measurement Frequency [Axis] Royalty interest sold, annual revenue threshold of highest tier Annual Revenue Threshold Annual Revenue Threshold Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Insider Trading Policies and Procedures [Line Items] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Adjustment to Compensation, Amount Adjustment to Compensation Amount Alnylam Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc [Member] Alnylam Pharmaceuticals, Inc Research and development accruals Accrued Research And Development Research and development accruals Payables and Accruals [Abstract] Compensation Amount Outstanding Recovery Compensation Amount Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Entity Small Business Entity Small Business Accounts payable and accrued liabilities Accounts Payable and Accrued Liabilities Disclosure [Text Block] Company Selected Measure Amount Company Selected Measure Amount Tabular List, Table Tabular List [Table Text Block] Level 3 Fair Value, Inputs, Level 3 [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Cash Investments and Cash Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Liability related to sale of future royalties Net liability related to sale of future royalties - beginning balance Net liability related to sale of future royalties - ending balance Liability Related To Sale Of Future Royalties, Noncurrent Liability Related To Sale Of Future Royalties, Noncurrent Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Issuance of common shares pursuant to ESPP (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Anti-dilutive common shares excluded from calculation of loss per common share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Contingencies and Commitments [Table] Contingencies and Commitments [Table] Net accretion and amortization of investments in marketable securities Accretion (Amortization) of Discounts and Premiums, Investments Sale Agreement Sale Agreement [Member] Sale Agreement Current assets: Assets, Current [Abstract] Number of royalty entitlements Royalty Entitlements Royalty Entitlements Non-cash royalty revenue Non-Cash Royalty [Member] Non-Cash Royalty Non-cash royalty revenue Liability From Sale Of Future Royalties, Non Cash Royalty Income Liability From Sale Of Future Royalties, Non Cash Royalty Income Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Product and Service [Domain] Product and Service [Domain] Employee Stock Option Share-Based Payment Arrangement, Option [Member] Sub-licensing revenue percentage Sub-licensing revenue Percentage Sub-licensing revenue Percentage Fair Value Disclosures [Abstract] Revenue from collaborations and licenses License [Member] Interest income Interest Income, Interest-Earning Asset Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Contingency, Pending Claims, Number Contingency, Pending Claims, Number Contingency, Pending Claims, Number Issuance of common shares pursuant to the Open Market Sale Agreement (in shares) Stock Issued During Period, Shares, New Issues, Open Market Sale Agreement Stock Issued During Period, Shares, New Issues, Open Market Sale Agreement Security Exchange Name Security Exchange Name Award Type Award Type [Axis] Reportable Segment Reportable Segment [Member] Reportable Segment Property and equipment, net of accumulated depreciation and impairment of $13,326 (December 31, 2024: $12,996) Property, Plant and Equipment, Net Payroll accruals Accrued Payroll Current Accrued Payroll Current Total liabilities Liabilities Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Research and development Research and Development Expense Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Expiration Date Trading Arrangement Expiration Date INVESTING ACTIVITIES Net Cash Provided by (Used in) Investing Activities [Abstract] Lease liability, current Operating Lease, Liability, Current Total Shareholder Return Amount Total Shareholder Return Amount Common shares, shares issued (in shares) Common Stock, Shares, Issued Future royalty payments Royalty Payable Represents the royalty payable. Entity [Domain] Entity [Domain] Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Accumulated depreciation of property and equipment Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Issuance of common shares pursuant to exercise of options (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Research and development Research and Development Expense [Member] Other segment expense Other segment expense Other segment expense Vaccitech Barinthus [Member] Barinthus Basis of presentation Basis of Accounting, Policy [Policy Text Block] Unrealized gain on available-for-sale securities OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax Diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Restructuring costs Restructuring Costs MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Other early research and development programs expense Other Research and Development Expense Total stockholders’ equity Beginning balance Ending balance Equity, Attributable to Parent Collaborations, contracts and licensing agreements Collaborative Arrangement Disclosure [Text Block] Litigation Case [Axis] Litigation Case [Axis] Balance Sheet Location [Axis] Statement of Financial Position Location, Balance [Axis] Interest expense Interest Expense, Nonoperating Recurring Fair Value, Recurring [Member] Accounts receivable Accounts Receivable, after Allowance for Credit Loss, Current Options granted during period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Sale of Stock [Domain] Sale of Stock [Domain] Other liabilities Increase (Decrease) in Other Operating Liabilities Long-term debt Long-Term Debt Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Document Fiscal Period Focus Document Fiscal Period Focus All Executive Categories All Executive Categories [Member] Balance Sheet Location [Domain] Statement of Financial Position Location, Balance [Domain] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Assets Assets [Abstract] Document Type Document Type Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Schedule of Segment Reporting Information, by Segment Schedule of Segment Reporting Information, by Segment [Table Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Contingent consideration Fair value of contingent consideration Liability at beginning of the period Liability at end of the period Business Combination, Contingent Consideration, Liability, Noncurrent Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost Issuance of common shares pursuant to the Open Market Sale Agreement Proceeds from Issuance of Common Stock, Open Market Sale agreement Proceeds from Issuance of Common Stock, Open Market Sale agreement Schedule of deferred collaborations and contracts revenue Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] US Government Securities, at Carrying Value US Government Securities, at Carrying Value Maximum Maximum [Member] Debt Securities, Available-for-Sale [Abstract] Debt Securities, Available-for-Sale [Abstract] Total deferred license revenue Contract with Customer, Liability Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Schedule of changes in fair value of contingent consideration Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Accounting Policies [Abstract] Revenue Revenues [Abstract] ONPATTRO ONPATTRO, global net sales [Member] ONPATTRO, global net sales Fair value measurements Fair Value Measurement, Policy [Policy Text Block] Current Fiscal Year End Date Current Fiscal Year End Date Accrued investment income receivable Accrued Investment Income Receivable Range [Axis] Statistical Measurement [Axis] Collaborations and licenses Collaboration And Contracts [Member] Collaboration And Contracts [Member] PEO Name PEO Name Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount All Award Types Award Type [Domain] Development and regulatory milestones payment per royalty, maximum License Agreement Maximum Development And Regulatory Milestone Payments Per Royalty License Agreement Maximum Development And Regulatory Royalty Payment per Royalty Name Outstanding Recovery, Individual Name Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Money Market Funds, at Carrying Value Money Market Funds, at Carrying Value Non-PEO NEO Non-PEO NEO [Member] Investments in marketable securities, current Investments, Fair Value Disclosure Additional Paid-In Capital Additional Paid-in Capital [Member] Award Timing Predetermined Award Timing Predetermined [Flag] Class of Stock [Line Items] Class of Stock [Line Items] Investment, Name [Axis] Investment, Name [Axis] Recent accounting pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Class of Stock [Axis] Class of Stock [Axis] Diluted (in USD per share) Earnings Per Share, Diluted Counterparty Name [Domain] Counterparty Name [Domain] Revenue from collaborations and licenses and Deferred Revenue Revenue from Contract with Customer [Policy Text Block] Name Measure Name Entity Interactive Data Current Entity Interactive Data Current Type of Restructuring [Domain] Type of Restructuring [Domain] Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Ownership [Axis] Ownership [Axis] Restructuring and related cost, number of positions eliminated, percent Restructuring and Related Cost, Number of Positions Eliminated, Period Percent Loss on impairment of leasehold improvements and lab equipment Restructuring, Settlement and Impairment Provisions Income taxes paid Income Taxes Paid Pending Litigation Pending Litigation [Member] Foreign exchange gain/(loss) Gain (Loss), Foreign Currency Transaction, before Tax Customer [Axis] Customer [Axis] Assets and liabilities measured at fair value on a recurring basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Employee Severance Employee Severance [Member] Statement of Financial Position [Abstract] US treasury bills US Treasury Bill Securities [Member] Stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Entity number of employees Entity Number of Employees Realized gains or losses Debt Securities, Realized Gain (Loss) Financial Instruments, Owned, US Government and Agency Obligations, at Fair Value Financial Instruments, Owned, US Government and Agency Obligations, at Fair Value Investments in marketable short-term securities Debt Securities, Available-for-Sale, Current OMERS OMERS [Member] OMERS Total other income Nonoperating Income (Expense) Cash Equivalents, at Carrying Value Cash Equivalents, at Carrying Value Net cash provided by investing activities Net Cash Provided by (Used in) Investing Activities Loss from operations Operating Income (Loss) Number of reportable segments Number of Reportable Segments Total liabilities and stockholders’ equity Liabilities and Equity Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] All Adjustments to Compensation All Adjustments to Compensation [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Other deferred costs, gross Other Deferred Costs, Gross Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Additional paid-in capital Additional Paid in Capital Operating Lease, Impairment Loss Operating Lease, Impairment Loss Restructuring Restructuring Charges Commitments and Contingencies Disclosure [Abstract] Legal Entity [Axis] Legal Entity [Axis] Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table] Earnings Per Share, Basic, by Common Class, Including Two-Class Method [Table] Interest income Investment Income, Interest Sale of future royalties Liabilities Related To Sale Of Future Royalties [Text Block] Liabilities Related To Sale Of Future Royalties Underlying Security Market Price Change Underlying Security Market Price Change, Percent Premium on closing stock price (as a percent) Premium on Closing Stock Price Premium on Closing Stock Price Individual: Individual [Axis] Issuance of common shares upon vesting of RSUs Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] Arbutus Inc. Arbutus Inc. [Member] Arbutus Inc. [Member] Change in fair value of contingent consideration Increase (Decrease) In Fair Value Of Contingent Consideration Liability Increase (Decrease) In Fair Value Of Contingent Consideration Liability Product and Service [Axis] Product and Service [Axis] Entity Address, State or Province Entity Address, State or Province Statement [Line Items] Statement [Line Items] Schedule of Equity Method Investments [Line Items] Schedule of Equity Method Investments [Line Items] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Trade accounts payable Accounts Payable, Trade, Current Operating expenses Operating Expenses [Abstract] Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Financial Instruments [Domain] Financial Instruments [Domain] Grant date fair value (in USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Liabilities and stockholders’ equity Liabilities and Equity [Abstract] Debt Securities, Unrealized Gain (Loss) Debt Securities, Unrealized Gain (Loss) Bona fide collaboration Percentage Bona fide collaboration Percentage Bona fide collaboration Percentage Minimum Minimum [Member] Restatement Determination Date Restatement Determination Date Registration Statement [Axis] Registration Statement [Axis] Registration Statement Adoption Date Trading Arrangement Adoption Date Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Genevant Genevant Sciences Corporation [Member] Genevant Sciences Corporation [Member] Schedule of Research and Development Arrangement, Contract to Perform for Others [Table] Research and Development, Contract to Perform for Others [Table] Right of use asset Operating Lease, Right-of-Use Asset Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Cash Equivalents, Fair Value Disclosure Cash Equivalents, Fair Value Disclosure Cash Equivalents, Fair Value Disclosure Segments [Axis] Segments [Axis] Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Imdusiran IM-PROVE I, II & III clinical trials expense Imdusiran IM-PROVE I, II & III Clinical Trials Expense Imdusiran IM-PROVE I, II & III Clinical Trials Expense Exercise Price Award Exercise Price Restructuring, Impairment, and Other Activities Disclosure Restructuring, Impairment, and Other Activities Disclosure [Text Block] Arrangement Duration Trading Arrangement Duration Issuance of common shares pursuant to ESPP Stock Issued During Period, Value, Employee Stock Purchase Plan Issuance of common shares pursuant to ESPP Stock Issued During Period, Value, Stock Options Exercised Stockholders’ equity Equity, Attributable to Parent [Abstract] Marketable Securities [Table] Marketable Securities [Table] Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Segments [Domain] Segments [Domain] Restructuring Plan [Axis] Restructuring Plan [Axis] Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] All Individuals All Individuals [Member] PEO PEO [Member] Name Trading Arrangement, Individual Name Statement of Stockholders' Equity [Abstract] Enantigen's Selling Shareholders Enantigen's Selling Shareholders [Member] Enantigen's Selling Shareholders Gross Unrealized Gain Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Assets Assets, Fair Value Disclosure [Abstract] Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Cash and cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Accounts payable and accrued liabilities Accounts payable and accrued liabilities Accounts Payable and Accrued Liabilities, Current Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Non-cash interest expense Non Cash Interest Expense Related To Sale Of Future Royalties Non Cash Interest Expense Related To Sale Of Future Royalties Local Phone Number Local Phone Number Other Liabilities Disclosure [Line Items] Other Liabilities Disclosure [Line Items] Other Liabilities Disclosure [Line Items] Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Gross proceeds from sale of royalty interest. before advisory fees Gross Proceeds From Royalty Interest Sold Gross Proceeds From Royalty Interest Sold Total operating expenses Operating Expenses Long Term Marketable Securities Investments in marketable securities, noncurrent [Member] Investments in marketable securities, noncurrent Accrual of lease-related operating expenses Other Restructuring [Member] Schedule of Equity Method Investments [Table] Equity Method Investment [Table] Jefferies LLC Jefferies LLC [Member] Jefferies LLC Irrevocable Deed of Trust of Michael J. Sofia [Member] Irrevocable Deed of Trust of Michael J. Sofia Debt securities, available-for-sale, unrealized loss Position, number of positions Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions Net change in operating items: Increase (Decrease) in Operating Capital [Abstract] PEO Total Compensation Amount PEO Total Compensation Amount Income Statement Location [Axis] Statement of Income Location, Balance [Axis] Contingencies and commitments Commitments and Contingencies Disclosure [Text Block] Impairment of laboratory equipment Impairment, Long-Lived Asset, Held-for-Use Common Shares Common Stock [Member] Measure: Measure [Axis] Share price (in USD per share) Share Price Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Potential milestone payments Potential Milestone Payments Represents the potential milestone payments amount. Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Entity Emerging Growth Company Entity Emerging Growth Company Total Liabilities, Fair Value Disclosure Number of wholly-owed subsidiaries Wholly Owned Subsidiaries Included in Financial Statements Represents the number of wholly owned subsidiaries included in the reporting of the financial statements. Segment Reporting [Abstract] Entity Central Index Key Entity Central Index Key Adjustments and reconciling items Segment Reporting, Other Segment Item, Amount General and administrative General and Administrative Expense [Member] Equity Method Investments and Joint Ventures [Abstract] Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Noncash modification of equity awards Other Restructuring Costs Research and Development Arrangement, Contract to Perform for Others [Line Items] Research and Development Arrangement, Contract to Perform for Others [Line Items] Development and regulatory milestones payment per licensed compound series, maximum License Agreement Maximum Development And Regulatory Milestone Payments Per License License Agreement, Maximum Development and Regulatory Milestone Payments Per License Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Royalty guarantees commitments percentage Royalty Guarantees Commitments Percentage Represents the royalty guarantees commitments percentage. Schedule of accounts payable and accrued liabilities Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Shareholders’ equity Equity [Text Block] Accounts payable and accrued liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Recovery of direct costs Recovery of Direct Costs Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Equity Component [Domain] Equity Component [Domain] Financial Instrument [Axis] Financial Instrument [Axis] Segment Reporting Disclosure Segment Reporting Disclosure [Text Block] Non-cash items: Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Change in fair value of contingent consideration Increase (decrease) in fair value of contingent consideration Change in fair value of liability Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Stock-based compensation expense APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Entity Shell Company Entity Shell Company Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Title Trading Arrangement, Individual Title Consolidated net loss Reconciliation of Operating Profit (Loss) from Segments to Consolidated Statement [Table] Statement [Table] Counterparty Name [Axis] Counterparty Name [Axis] Fair Value, Measurement Frequency [Domain] Measurement Frequency [Domain] Significant accounting policies Significant Accounting Policies [Text Block] Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] City Area Code City Area Code Current liabilities: Liabilities, Current [Abstract] Weighted average number of common shares Weighted Average Number Of Common Shares [Abstract] Weighted average number of common shares Non-cash royalty revenue Non-cash royalty revenue Non Cash Royalty Revenue Related To Sale Of Future Royalties Non Cash Royalty Revenue Related To Sale Of Future Royalties Non Cash Royalty Revenue Related To Sale Of Future Royalties Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Level 1 Fair Value, Inputs, Level 1 [Member] Stockholders' Equity Note [Abstract] Total current assets Assets, Current Statement of Cash Flows [Abstract] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Loss per share Earnings Per Share [Abstract] Arbutus Plans Arbutus Plans [Member] Arbutus Plans [Member] Deficit Retained Earnings (Accumulated Deficit) Class of Stock [Domain] Class of Stock [Domain] General and administrative General and Administrative Expense Organization, Consolidation and Presentation of Financial Statements [Abstract] Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Equity Awards Adjustments Equity Awards Adjustments [Member] Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Underlying Securities Award Underlying Securities Amount Investments in marketable securities Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Deferred license revenue, current Deferred Revenue, Current Deferred Revenue Arrangement [Line Items] Deferred Revenue Arrangement [Line Items] Amendment Flag Amendment Flag Entity Registrant Name Entity Registrant Name Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Depreciation Depreciation, Depletion and Amortization Research and development employee expense, lab supplies and overhead Research and development employee expense, lab supplies and overhead Research and development employee expense, lab supplies and overhead Fair Value as of Grant Date Award Grant Date Fair Value Number of shares issued under agreement (in sales) Sale of Stock, Number of Shares Issued in Transaction Level 2 Fair Value, Inputs, Level 2 [Member] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Non-cash interest expense Liability From Sale Of Future Royalties, Non Cash Interest Expense Liability From Sale Of Future Royalties, Non Cash Interest Expense Entitlement of royalties to be received Royalty Interest Sold, Maximum Royalties For Buyer Royalty Interest Sold, Maximum Royalties For Buyer Entity Address, Postal Zip Code Entity Address, Postal Zip Code Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Schedule of stock based compensation expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Principles of consolidation Consolidation, Policy [Policy Text Block] Schedule of Restructuring and Related Costs [Table] Restructuring Cost [Table] Restatement Determination Date: Restatement Determination Date [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Title of 12(b) Security Title of 12(b) Security Issued and outstanding: 191,481,474 (December 31, 2024: 189,963,492) Common Stock, Value, Issued Acuitas Therapeutics, Inc. Acuitas Therapeutics Inc. [Member] Acuitas Therapeutics Inc. Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Litigation Status [Axis] Litigation Status [Axis] Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] FINANCING ACTIVITIES Net Cash Provided by (Used in) Financing Activities [Abstract] Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Disposition of investments in marketable securities Proceeds from Sale, Maturity and Collection of Investments Basic (in USD per share) Earnings Per Share, Basic Transaction costs on sale of royalties Transaction Costs Related To Sale Of Future Royalties Transaction Costs Related To Sale Of Future Royalties Issuance of common shares pursuant to the Open Market Sale Agreement Proceeds from issuance of shares under the agreement Proceeds from Issuance of Common Stock Issuance of common shares pursuant to ESPP Proceeds from Stock Plans Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Other Liabilities Disclosure [Abstract] Ownership [Domain] Ownership [Domain] Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Michael J. Sofia [Member] Michael J. Sofia Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Schedule of Stock by Class [Table] Stock, Class of Stock [Table] Total current liabilities Liabilities, Current Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Total assets Assets Fair Value, Liabilities Measured on Recurring Basis [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis [Roll Forward] Summary of collaborations Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block] Restricted stock units granted during period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Contingencies and Commitments [Line Items] Contingencies and Commitments [Line Items] Cash and Cash Equivalents [Abstract] Cash and Cash Equivalents [Abstract] Acquisition of property and equipment Payments to Acquire Property, Plant, and Equipment Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Investment in Genevant Equity Method Investments and Joint Ventures Disclosure [Text Block] Qilu Pharmaceutical Co, LTD. Qilu Pharmaceutical Co, LTD. [Member] Qilu Pharmaceutical Co, LTD. Termination Date Trading Arrangement Termination Date Amortization of other deferred charges Amortization of Other Deferred Charges Nature of business and future operations Nature of Operations [Text Block] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Revenues Revenues Entity Address, City or Town Entity Address, City or Town Proceeds from collaborators Proceeds from Collaborators Allocated share-based compensation expense Share-Based Payment Arrangement, Expense Net loss Net loss Segment net loss Net Income (Loss) Attributable to Parent Trading Arrangement: Trading Arrangement [Axis] Investments, Debt and Equity Securities [Abstract] Weighted average exercise price (in USD per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Gain Contingencies [Table] Loss Contingencies [Table] Business Acquisition [Axis] Business Acquisition [Axis] Schedule of activity related to the net liability from inception of the Agreement Liabilities Related To Sale Of Future Royalties Roll Forward [Table Text Block] Liabilities Related To Sale Of Future Royalties Roll Forward US corporate bonds US Corporate Bonds [Member] US Corporate Bonds Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Entity File Number Entity File Number Liabilities Liabilities, Fair Value Disclosure [Abstract] Document Fiscal Year Focus Document Fiscal Year Focus Revenue from External Customers by Products and Services [Table] Segment Reporting, Revenue from External Customer, Product and Service [Table] Income Statement [Abstract] Entity Address, Address Line One Entity Address, Address Line One Effect of foreign exchange rate changes on cash and cash equivalents Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Cash severance Severance Costs Restructuring Plan [Domain] Restructuring Plan [Domain] Total Assets, Fair Value Disclosure Name Forgone Recovery, Individual Name Royalty interest, % interest Royalty interest, Percent interest Royalty interest, % interest Document Period End Date Document Period End Date Sale of Stock [Axis] Sale of Stock [Axis] Deferred license revenue, non-current Deferred Revenue, Noncurrent Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Change in deferred license revenue Increase (Decrease) in Deferred Revenue Insider Trading Arrangements [Line Items] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Marketable securities Marketable Securities [Table Text Block] Cumulative Collaboration Revenue Recognized Contract with Customer, Liability, Revenue Recognized Registration Statement [Domain] Registration Statement [Domain] Registration Statement [Domain] Adjustment to Compensation: Adjustment to Compensation [Axis] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Document Transition Report Document Transition Report Document Quarterly Report Document Quarterly Report Liability Related To Sale Of Future Royalties [Roll Forward] Liability Related To Sale Of Future Royalties [Roll Forward] Liability Related To Sale Of Future Royalties [Roll Forward] Litigation Case [Domain] Litigation Case [Domain] Customer [Domain] Customer [Domain] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Current Reporting Status Entity Current Reporting Status Deficit Retained Earnings [Member] Noncontrolling interest, ownership percentage by noncontrolling owners Subsidiary, Ownership Percentage, Noncontrolling Owner Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Litigation Status [Domain] Litigation Status [Domain] Impairment of leasehold improvements Impairment of Leasehold Basic (in shares) Weighted Average Number of Shares Outstanding, Basic Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Modification of Equity Awards Modification of Equity Awards [Member] Modification of Equity Awards Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Unrealized gain on available-for-sale securities Debt Securities, Available-for-Sale, Unrealized Gain (Loss) Professional fee accruals Accrued Professional Fees, Current Executive Category: Executive Category [Axis] Purchase of investments in marketable securities Payments to Acquire Investments Name Awards Close in Time to MNPI Disclosures, Individual Name Entity Filer Category Entity Filer Category Revenue, remaining performance obligation, amount Revenue, Remaining Performance Obligation, Amount Income Statement Location [Domain] Statement of Income Location, Balance [Domain] Arbutus Biopharma Corp Arbutus Biopharma Corp [Member] Arbutus Biopharma Corp Gain Contingencies [Line Items] Loss Contingencies [Line Items] Company Selected Measure Name Company Selected Measure Name